Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction

31 August 2025 (13:15 - 14:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Joseph Kassab

UT Southwestern Medical Center, Dallas (United States of America)

5 More presentations in this session

Presentation thumbnail

Insights into pulmonary remodelling in heart failure with preserved ejection fraction through transpulmonary biomarker gradients

Doctor M. Dagan (Melbourne, AU)

Abstract Slides Video

Presentation thumbnail

Small left ventricle in patients with heart failure with preserved ejection fraction is associated with higher mortality

Doctor Y. Nakagawa (Kawanishi, JP)

Abstract Slides Video

Presentation thumbnail

Phenogrouping HFpEF trajectories identifies early and end-stage subtypes: a multicentre study using natural language processing

Doctor S. Brown (London, GB)

Abstract Slides Video

Presentation thumbnail

Gender-specific outcomes and treatment responses in elderly HFpEF patients: a comprehensive single-center retrospective study

Doctor K. Shi (Shanghai, CN)

Abstract Slides Video

Presentation thumbnail

Characteristics of pulmonary hypertension in adults with left ventricular diastolic dysfunction

Doctor S. Ratwatte (London, GB)

Abstract Slides Video

Access the full session

Session thumbnail

HFpEF issues

The Event

Event poster

ESC Congress 2025

31 August 2025 13:15 CET

You may be interested in

Congress Session

Further Insights into SGLT2i treatment for heart failure

Congress Presentation

Outcomes of empagliflozin versus dapagliflozin treatment in patients with heart failure based on left ventricular ejection fraction: a multicentre cohort study

Congress Presentation

Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources